Correct use of proton pump inhibitors for gastro-oesophageal reflux disease.

J. Hatlebakk,B. Emken,V. Glazkov,D. Hoff,T. Hausken

DOI: https://doi.org/10.4045/tidsskr.12.0019

2013-01-08

Abstract:Gastro-oesophageal reflux disease is the most common disease affecting the upper gastrointestinal tract and affects all age groups, from infants to the aged. Approximately 8 % of adults meet the diagnostic criteria for GORD. In many cases the symptoms act as a constraint on everyday living and quality of life (1), and the indirect costs to society in terms of reduced productivity may be substantial (2). The disease is chronic in most cases, but often with varying need for treatment over time. The most effective medical treatment for acid reflux is proton pump inhibitors (PPI), which inhibit the acid secretion of the stomach more strongly and with a longer duration of action than other available drugs (3). The consumption of these medicines in Norway is lower than elsewhere in Europe, but has increased by up to 10 % annually in the period 2003 – 2008 (4). Both overuse and under-use are undesirable, and it is important that the drugs be used optimally. This article is intended to provide practice advice on the use of proton pump inhibitors for acid reflux disease and is based on searches in PubMed, the authors’ own clinical experience and research, and Norwegian reimbursement rules for prescription drugs.